BLONAY, Switzerland and WILMINGTON, Del., Sept. 22, 2026 /PRNewswire/ -- Ammonix today emerged from stealth with a new AI architecture that combines a fast, specialized System One decision-making architecture with a System Two language model for reasoning and interaction.

The architecture is designed to create specialist AI agents that learn from a company's operational data and workflows. It enables fast responses, auditable recommendations, control over sensitive data, and predictable computing. Within broader agentic systems, Ammonix agents can serve as intelligent control layers for critical functions, making AI systems safer, faster, and more reliable.
The company is led by co-founder and CEO Peter Ruppersberg, a scientist and serial entrepreneur whose medical AI company, Cortex, was acquired by Boston Scientific in January 2025 for up to $300 million.
Unlike general-purpose AI, Ammonix agents are built around specific principles: they learn from an organization's data, reach expert-level performance from a few hundred examples, and improve over time by updating their memory. Every recommendation is fast and auditable, with supporting examples available for verification. When an agent does not know, it asks for human input rather than guessing, an approach designed for high-stakes applications. By capturing expertise once and reusing it across tasks, Ammonix agents can run on local hardware, dramatically reducing compute requirements and costs while enhancing data privacy, security, and operational control.
Ammonix demonstrates its architecture across four applications: ECG interpretation, healthcare claims collection, waste-to-energy control-room support, and applied computer vision. In these applications, the agents matched or outperformed OpenAI's GPT-6 at lower cost and significantly faster speeds.
"Enterprise AI cannot simply be another expensive model with more parameters," said Peter Ruppersberg. "Companies need agents built around their own operational requirements that respect boundaries, provide verifiable evidence behind their conclusions, and remain economically deployable."
Peter Ruppersberg began his career in a Nobel Prize-winning research team and later became a full professor and department head, publishing in Nature and Science and filing numerous patents. He subsequently founded several companies, including Mentasys, an AI product-search pioneer acquired by Lycos in 2006.
Ammonix will soon release AmmonixCode, a source-available coding platform for building agents with the Ammonix architecture. It will be free for research and evaluation, with commercial and enterprise licenses available at licensing@ammonix.ai.
To learn more, visit www.ammonix.ai.
Media Contact: contact@ammonix.ai

Photo - https://mma.prnewswire.com/media/3009048/ammonix.jpg
Logo - https://mma.prnewswire.com/media/3009049/ammonix_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ammonix-launches-a-new-ai-architecture-for-high-stakes-specialist-agents-that-outperform-frontier-models-at-a-lower-cost-302885148.html

Während die Dieselpreise in Teilen Italiens neue Höchststände erreichen, zeichnet sich in Luxemburg eine spürbare Entspannung ab – und in Deutschland profitieren Autofahrer nur eingeschränkt von Steuererleichterungen. In Südtirol kletterte der Dieselhöchstpreis in Bozen Medienberichten...
Sandro Brotz kehrt dem Schweizer Radio und Fernsehen den Rücken und wechselt Anfang 2027 zur Boulevardzeitung «Blick». Der 56-jährige Journalist, derzeit Moderator und stellvertretender Leiter der Polit-Talksendung «Arena», wird SRF Ende Januar 2027 verlassen. Bis voraussichtlich Mitte Januar...

Inflationssorgen und steigende Ölpreise haben Europas wichtigste Aktienmärkte zur Wochenmitte spürbar belastet und zugleich die Monatsbilanz eingetrübt. Der EuroStoxx 50 schloss am Mittwoch 0,81 Prozent tiefer bei 6269,02 Punkten. Im Monatsverlauf verlor der Leitindex der Eurozone 2,4 Prozent...

Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur...

Eine anonyme E-Mail an die US-Botschaft in Bern hat kurz vor dem Auftritt von US-Präsident Donald Trump beim Weltwirtschaftsforum in Davos ein Ermittlungsverfahren der Schweizer Bundesanwaltschaft ausgelöst – und zur Festnahme einer WEF-Mitarbeiterin geführt. Inzwischen ist klar: Die gegen...